KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Retained Earnings: 2009-2025

Historic Retained Earnings for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to -$2.4 billion.

  • Ionis Pharmaceuticals' Retained Earnings fell 11.95% to -$2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 billion, marking a year-over-year decrease of 11.95%. This contributed to the annual value of -$2.2 billion for FY2024, which is 25.27% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Retained Earnings is -$2.4 billion, which was down 5.66% from -$2.3 billion recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Retained Earnings peaked at -$1.2 billion during Q4 2021, and registered a low of -$2.4 billion during Q3 2025.
  • Its 3-year average for Retained Earnings is -$2.0 billion, with a median of -$2.0 billion in 2024.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Retained Earnings crashed by 52.30% in 2021 and then rose by 0.53% in 2022.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Retained Earnings stood at -$1.2 billion in 2021, then fell by 23.25% to -$1.4 billion in 2022, then dropped by 25.62% to -$1.8 billion in 2023, then decreased by 25.27% to -$2.2 billion in 2024, then decreased by 11.95% to -$2.4 billion in 2025.
  • Its last three reported values are -$2.4 billion in Q3 2025, -$2.3 billion for Q2 2025, and -$2.4 billion during Q1 2025.